Genotoxicity of irinotecan and its modulation by vitamins A, C and E in human lymphocytes from healthy individuals and cancer patients

Toxicology in Vitro

Volumn 24, Issue 2, 2010, Pages 417-424

  Kontek, R ^a   Drozda, R ^b   Sliwinski M ^a   Grzegorczyk, K ^c  

^a UNIVERSITY OF LODZ   (Poland)

^b Hospital of the Ministry of Interior Affairs and Administration   (Poland)

^c Medical University of Lodz Bieganski Hospital   (Poland)

Author keywords

Comet assay; DNA repair; Genotoxicity; Irinotecan; Vitamins

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; IRINOTECAN; RETINOL;

ADULT; ARTICLE; CLINICAL ARTICLE; COLORECTAL CARCINOMA; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG POTENTIATION; FEMALE; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE; MALE;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASCORBIC ACID; CAMPTOTHECIN; COMET ASSAY; DNA DAMAGE; DNA REPAIR; FEMALE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; MUTAGENS; VITAMIN A; VITAMIN E;

EID: 76549094391     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2009.10.013     Document Type: Article

References (41)

1. Arabski M., Kaźmierczak P., Wiśniewska-Jarosińska M., Drzewoski J., and Błasiak J. Interaction of amoxicillin with DNA in human lymphocytes and H. pylori-infected and non-infected gastric mucosa cells. Chemico-Biological Interactions 52 1 (2005) 13-24
2. Barnes D.E. Non-homologous end joining as a mechanism of DNA repair. Current Biology 11 (2001) 455-457
3. Błasiak J., Gloc E., Woźniak K., Młynarski W., Stolarska M., Skórski T., and Majsterek I. Genotoxicity of idarubicin and its modulation by vitamins C and E and amifostine. Chemico-Biological Interaction 140 1 (2002) 1-18
4. Błasiak J., Gloc E., Drzewoski J., Zadrożny M., Skórski T., and Pertyński T. Free radical scavengers can differentially modulate the genotoxicity of amsacrine in normal and cancer cells. Mutation Research 535 1 (2003) 25-34
5. Block K.I., Koch A.C., Mead M.N., Tothy P.K., Newman R.A., and Gyllenhaal Ch. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. International Journal of Cancer 123 (2008) 1227-1239
6. Burgess D.J., Doles J., Zender L., Xue W., Ma B., McCombie W.R., Hannon G.J., Lowe S.W., and Hemann M.T. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proceedings of the National Academy of Sciences of the USA 105 26 (2008) 9053-9058
7. Da Violante G., Zerrouk N., Richard I., Provot G., Chaumeil J.C., and Arnaud P. Evaluation of the cytotoxicity effect of dimethyl sulfoxide (DMSO) on Caco2/TC7 colon tumor cell cultures. Biological and Pharmaceutical Bulletin 25 12 (2002) 1600-1603
8. D'Andrea G.M. Use of antioxidants during chemotherapy and radiotherapy should be avoided. Cancer Journal for Clinicians 55 5 (2000) 319-321
9. Derks S., Bosch L.J., Niessen H.E., Moerkerk P.T., van den Bosch S.M., Carvalho B., Mongera S., Voncken J.W., Meijer G.A., de Bruïne A.P., Herman J.G., and van Engeland M. Promoter CpG island hypermethylation - and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21. Carcinogenesis 30 6 (2009) 1041-1048
10. Douillard J.Y., Cunningham D., Roth A.D., Nawarro M., James R.D., Karasek P., Jandik P., Iveson T., Carmichael J., Alakl M., Gruia G., Awad L., and Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355 (2000) 1041-1047
11. Dudas A., and Chovanec M. DNA double-strand break repair by homologous recombination. Mutation Research 566 (2004) 131-167
12. Fenech M., and Ferguson L.R. Vitamins/minerals and genomic stability in humans. Mutation Research 475 (2001) 1-6
13. Feyruz V.R. DNA double strand breaks (DSB) and non-homologous end joining (NHEJ) pathways in human leukemia. Cancer Letters 193 (2003) 1-9
14. Fuchs Ch., Mitchell E.P., and Hoff P.M. Irinotecan in the treatment of colorectal cancer. Cancer Treatment Reviews 32 (2006) 491-503
15. Gackowski D., Banaszkiewicz Z., Rozalski R., Jawien A., and Olinski R. Persistent oxidative stress in colorectal carcinoma patients. International of Journal Cancer 101 (2002) 395-397
16. Hefferin M.L., and Tomkinson A.E. Mechanism of DNA double-strand break repair by non-homologous end joining. DNA Repair 4 6 (2005) 639-648
17. Helleday T., Lo J., van Gent D.C., and Engelward B.P. DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair 6 (2007) 923-935
18. Hu Y., and Villalona-Calero M.A. Irinotecan: mechanism of tumor resistance and novel strategies for modulating its activity. Annals of Oncology 13 (2002) 1841-1851
19. Kassie F., Parzefall W., and Knasmuller S. Single cell gel electrophoresis assay: a new technique for human biomonitoring studies. Mutation Research 463 (2000) 13-31
20. Końca K., Lankoff A., Banasik A., Lisowska H., Kuszewski T., Góźdź S., Koza Z., and Wojcik A. A cross-platform public domain PC image-analysis program for the comet assay. Mutation Research 534 (2003) 15-20
21. Kopjar N., Źeljeźić D., Vrdoljak A.L., Radić B., Ramić S., Milić M., Gamulin M., Pavlica V., and Fućić A. Irinotecan toxicity to human blood cells in vitro: relationship between various biomarkers, Nordic Pharmacological Society. Basic and Clinical Pharmacology and Toxicology 100 (2007) 403-413
22. Kosmidis P.A., and Manegold C. Advanced NSCLC: new cytostatic agents. Lung Cancer 41 (2003) 123-132
23. Ladas E.J., Jacobson J.S., Kennedy D.D., Teel K., Fleischauer A., and Kelly K.M. Antioxidants and cancer therapy: a systematic review. Journal of Clinical Oncology 22 3 (2004) 517-528
24. Markovitz S.D., Dawson D.M., Willis J., and Willson J.K.V. Focus on colon cancer. Cancer Cell 1 (2002) 233-236
25. Mathijssen R.H., van Alphen R.J., Verweij J., Loos W.J., Nooter K., Stoter G., and Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clinical Cancer Research 7 8 (2001) 2182-2194
26. Mathijssen R.H., Loos W.J., Verweij J., and Sparreboom A. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Current Cancer Drug Target 2 (2002) 103-123
27. Pavillard V., Agostini C., Richard S., Charasson V., Montaudon D., and Robert J. Determinant of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemotherapy and Pharmacology 49 (2002) 329-335
28. Pfeiffer P., Goedecke W., and Obe G. Mechanism of DNA double strand break repair and their potential to induce chromosomal aberrations. Mutagenesis 15 (2001) 289-302
29. Pizzolato J.F., and Saltz L. The camptothecins. Lancet 361 (2003) 2235-2242
30. Rajaee-Behbahani N., Schmezer P., Risch A., Rittgen W., Keiser K.W., Dienemann H., Schulz V., Drings P., Thiel S., and Bartsch H. Altered DNA repair capacity and bleomycin sensitivity as risk markers for non-small cell lung cancer. International Journal of Cancer 95 (2001) 86-91
31. Rassool F.V. DNA double strand breaks (DSB) and non-homologous end joining (NHEJ) pathways in human leukemia. Cancer Letters 193 (2003) 1-9
32. Robichova S., Slamenova D., Chalupa I., and Sebova L. DNA lesions and cytogenetic changes induced by N-nitrosomorpholine in HepG2, V79 and VH10 cells: the protective effects of vitamins A, C and E. Mutation Research 560 (2004) 91-99
33. Sapra P., Zhao H., Mehlig M., Malaby J., Kraft P., Longley C., Greenberger L.M., and Horak I.D. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clinical Cancer Research 14 6 (2008) 1888-1896
34. Singh N.P., McCoy T., Tice R.R., and Schneider E.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Experimental Cell Research 175 (1988) 184-192
35. Śliwiński T., Rożej W., Morawiec-Bajda A., Morawiec Z., Reiter R.J., and Błasiak J. Protective action of melatonin against oxidative DNA damage: chemical inactivation versus base-excision repair. Mutation Research 634 1-2 (2007) 220-227
36. Tice R.R., Agurell E., Anderson D., Burlinson B., Hartmann A., Kobayashi H., Miyamae Y., Rojas E., Ryu J.C., and Sasaki Y.F. Single gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environmental and Molecular Mutagenesis 35 (2000) 206-221
37. Valko M., Rhodes C.J., Moncol J., Izakovic M., and Mazur M. Free radicals, metals antioxidants in oxidative stress-induced cancer. Chemico-Biological Interactions 160 1 (2006) 1-40
38. Wenzel U., Nickel A., Kuntz S., and Daniel H. Ascorbic acid suppresses drug-induced apoptosis in human colon cancer cells by scavenging mitochondrial superoxide anions. Carcinogenesis 25 5 (2004) 703-712
39. Woźniak K., and Błasiak J. In vitro genotoxicity of lead acetate: induction of single and double DNA strand breaks and DNA-protein cross-links. Mutation Research 535 (2003) 127-139
40. Woźniak K., Czechowska A., and Błasiak J. Cisplatin-evoked DNA fragmentation in normal and cancer cells and its modulation by free radical scavengers and the tyrosine kinase inhibitor STI571. Chemico-Biological Interactions 147 3 (2004) 309-318
41. Young A.J., and Lowe G.M. Antioxidant and prooxidant properties of carotenoids. Archives of Biochemistry and Biophysics 385 (2001) 20-27